FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Wash

Washington, D.C. 20549	OMB APPROVAL		
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-02	

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

932 SOUTHWOOD BOULEVARD

3235-0287 OMB Number: Estimated average burden hours per response: 0.5

10% Owner

below)

Other (specify

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) 2. Issuer Name and Ticker or Trading Symbol 1. Name and Address of Reporting Person* PDL BIOPHARMA, INC. [PDLI] Sandman Paul W Director Officer (give title below) (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) 06/09/2017 C/O PDL BIOPHARMA, INC.

(0++)					4. If <i>i</i>										6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	Б														X	Forn	n filed by One	e Rep	orting Pers	on	
INCLINI VILLAG	- N	V 8	39451													Form filed by More than One Reporting Person					
(City)	(St	ate) (Zip)																		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
1. Title of Security (Instr. 3)				2. Transaction Date (Month/Day/Year)		Exe	2A. Deemed Execution Date, if any (Month/Day/Year)				4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)				l and Secur Benef Owne		icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Cod	e v	,	Amount		A) or D)	Price	, l	Reported Transaction(s) (Instr. 3 and 4)				(111501.4)	
Common stock			06/09/2017				A			60,729	(1) A \$2.4		.47	7 208,452		D					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Gecurity or Exercise (Month/Day/Year) if any		Date,	ate, Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	Expira	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)			8. Price Derivati Security (Instr. 5		derivative Securities	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
												Am	ount								

Explanation of Responses:

1. The grant will cliff-vest on the first anniversary of the date of grant so long as the grant recipient continues to serve on the Board of Directors of PDL BioPharma, Inc. During the one-year vesting period, the grant recipient will have the right to vote the shares and receive any dividends and other distributions paid, except that dividends and other distributions will be accumulated and will vest and be paid, with interest, on the earlier of the same vesting conditions as the original award or March 15th of the year following the payment of such dividend or distribution to all stockholders.

Exercisable

(D)

Remarks:

/s/ Nathan N. Kryszak,

or Number

of Shares

06/12/2017 Attorney-in-Fact for Paul W.

Sandman

Title

Expiration

Date

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.